Characterization of multiple driver alterations in acquired resistance to osimertinib in EGFR-mutated lung cancer: implementation of single cell approaches

被引：0

作者：

Chen, Jeanne ^{[1
]}

Braye, Floriane ^{[1
]}

Facchinetti, Francesco ^{[1
]}

Lacroix, Ludovic ^{[1
]}

Scoazec, Jean-Yves ^{[1
]}

Tselikas, Lambros ^{[1
]}

Planchard, David ^{[1
]}

Mezquita, Laura ^{[1
]}

Gazzah, Anas ^{[1
]}

Naltet, Charles ^{[1
]}

Lavaud, Pernelle ^{[1
]}

Maillard, Aline ^{[1
]}

Michiels, Stefan ^{[1
]}

Massard, Christophe ^{[1
]}

Olaussen, KenA ^{[1
]}

Andr, Fabrice ^{[1
]}

Vassal, Gilles ^{[1
]}

Soria, Jean-Charles ^{[1
]}

Besse, Benjamin ^{[1
]}

Friboulet, Luc ^{[1
]}

机构：

[1] Inst Gustave Roussy, Villejuif, France

来源：

CANCER RESEARCH | 2020年 / 80卷 / 16期

关键词：

D O I：

10.1158/1538-7445.AM2020-1867

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1867

引用

页数：2

共 50 条

[41] Identification and in silico structural insights of rare recurrent EGFR mutations as resistance mechanisms to osimertinib in EGFR-mutated lung cancer.
Na Zhoutong
Wu, Changling
Lu, Binbin
Cao, Ran
Ma, Yutong
Bao, Hua
Ou, Qiuxiang
Wu, Xue
Shao, Yang
Wang, Zhaoxia
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[42] OsimertinibAcquired resistance in EGFR-mutated lung cancer: case report
Reactions Weekly, 2021, 1836 (1) : 619 - 619
[43] Chemotherapy with or without immunotherapy or bevacizumab for EGFR-mutated lung cancer after progression on osimertinib
White, M.
Neal, J. W.
Gardner, R. M.
Cunanan, K. M.
Das, M.
Padda, S. K.
Ramchandran, K.
Chen, T. T.
Wakelee, H.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S773 - S774
[44] EGFR-Mutated Lung Cancer With T790M-Acquired Resistance in the Brain and Histologic Transformation in the Lung
Scher, Kevin S.
Saldivar, Juan-Sebastian
Fishbein, Michael
Marchevsky, Alberto
Reckamp, Karen L.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (09): : 1040 - 1044
[45] Kinase Fusions as Recurrent Mechanisms of Acquired Resistance in EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)
Ou, S.
Klempner, S.
Creelan, B.
Hsieh, W. S.
Costin, D.
Stephens, P. J.
Ross, J.
Miller, V.
Ali, S.
Schrock, A.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1848 - S1848
[46] Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers
Vojnic, Morana
Kubota, Daisuke
Kurzatkowski, Christopher
Offin, Michael
Suzawa, Ken
Benayed, Ryma
Schoenfeld, Adam J.
Plodkowski, Andrew J.
Poirier, John T.
Rudin, Charles M.
Kris, Mark G.
Rosen, Neal X.
Yu, Helena A.
Riely, Gregory J.
Arcila, Maria E.
Somwar, Romel
Ladanyi, Marc
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (05) : 802 - 815
[47] Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance
Araki, Taisuke
Kanda, Shintaro
Horinouchi, Hidehito
Ohe, Yuichiro
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (07) : 547 - 561
[48] Molecular genotyping on liquid biopsies for assessment of resistance mechanisms to osimertinib in patients with EGFR-mutated non-small-cell lung cancer
Demidova, I.
Barinov, A.
Gorokhov, A.
Reutova, E.
Moiseenko, F.
Laktionov, K.
VIRCHOWS ARCHIV, 2024, 485 : S132 - S132
[49] Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer A meta-analysis
Huang, Lei
Huang, Hao
Zhou, Xiao-Ping
Liu, Jin-Feng
Li, Chun-Rong
Fang, Min
Wu, Jun-Rong
MEDICINE, 2019, 98 (43)
[50] Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?
Patel, Shruti R.
Neal, Joel W.
TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (07) : 1631 - 1635

← 1 2 3 4 5 →